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Non-paraneoplastic limbic
encephalitis associated with
NMDAR and VGKC antibodies
INTRODUCTION
Limbic encephalitis (LE) is characterised by
seizures and impairment of short-term
memory as well as behavioural and psychi-
atric symptoms such as anxiety, depression,
personality change and hallucinations. Onset
of these symptoms is typically subacute over
a few weeks or months but may also evolve
over a few days. In many patients, limbic
encephalitis is a paraneoplastic syndrome us-
ually preceding diagnosis of the malignancy.
Associated tumours are most commonly
small-cell lung cancer (SCLC), breast cancer,
testicular tumour, teratoma, Hodgkin lym-
phoma and thymoma.1 Antineuronal auto-
antibodies can be detected in the sera of about
60% of patients. These autoantibodies are
classically directed to intracellular antigens
(eg, anti-Hu, anti-Ma1/2, anti-CRMP5/CV2,
anti-amphiphysin). However, LE is now be-
ing recognised frequently in the absence of
malignancy and can be associated with anti-
bodies to voltage-gated potassium channel
(VGKC-ab). More recently, a new type of
immunotherapy-responsive severe LE was
described by Dalmau and colleagues that is
associated with antibodies to the N-methyl-
D-aspartate-receptor (NMDAR) and ovarian
teratoma. In rare instances, these NMDAR-
ab also occur in men with testicular tera-
toma or SCLC.2 3 For the first time, we
describe a male patient with non-paraneo-
plastic limbic encephalitis and with serum
antibodies to both NMDAR and VGKC.
CASE REPORT
This previously healthy 56-year-old man
reported the first signs of disease in 2007
when he recognised hypersomnia and pro-
gressive generalised myoclonus while sleep-
ing. Additionally, he developed short-term
memory loss, concentration deficits and dis-
orientation. All these symptoms evolved
over 6 months. At this point of time, the
patient experienced his first epileptic seizure.
However, there was no evidence for neuro-
myotonia.
Neuropsychological testing revealed severe
verbal amnestic syndrome. MRI of the brain
showed bitemporal T2- and fluid-attenuated
inversion recovery-hyperintense lesions. There
was no evidence of contrast enhancement in
the T1-weighted sequences (figure 1). EEG
showed diffuse slowing and focal epileptic
activity in the left temporal lobe. Repetitive
cerebrospinal fluid (CSF) investigations re-
vealed normal values for lymphocytes and
protein. Serum and CSF revealed the same
oligoclonal IgGbands. Serumanalysis showed
slight hyponatraemia (129 mmol/l), which
resolved completely during the following
weeks. Blood cell count, thyroid function test
including thyroid autoantibodies, antibodies
to double-stranded DNA, and SSA/Ro and
SSB/La were unremarkable. Paraneoplastic
antineuronal antibodies (Hu, Ri, Yo, Ma1,
Ma2, Recoverin, CRMP5/CV2), tumour
markers and screening for infectious disease
such as, herpes simplex virus IgG and PCR
were all negative. Limbic encephalitis was
diagnosed according to reviewed diagnostic
criteria.4 Oral methylprednisolone therapy
(1 mg/kg body weight) followed by oral
tapering to 5 mg per day led to a marked
clinical improvement during the following
weeks. Therefore, steroid therapy was
continued with this dosage. Seizures were
treated with levetiracetam (1 g twice daily)
successfully.
One year after onset of symptoms, he was
seen in our institute for the first time. We
obtained positive results for VGKC-ab at
a level of 392 pM (normal <100 pM) as well
as for NMDAR-ab (scoring 2 on a range from
0 (negative) to 4 (highly positive) (Irani S,
Vincent A unpublished results)). Repetitive
testing 3 months later confirmed both of
these positive results (NMDAR-ab 2; VGKC-
ab 281 pM). An extensive tumour search in-
cluding positron emission tomography with
fluor-desoxyglucose in combination with CT
(FDG-PET/CT) of the whole body did not
reveal an underlying neoplasm. Urological
examination including ultrasound of the
testis gave no evidence for testicular cancer.
Figure 1 Brain MRI findings at onset of symptoms. (A) Fluid-attenuated inversion recovery
showing hyperintensity asymmetrically involving both medial temporal lobes. (B) Contrast-
enhanced T1 images. No gadolinium uptake was shown.
J Neurol Neurosurg Psychiatry December 2010 Vol 81 No 12 1407
PostScript
 group.bmj.com on January 21, 2014 - Published by jnnp.bmj.comDownloaded from 
Brain MRI revealed complete remission of
the right temporal lobe lesion and partial
remission of the lesion in the left temporal
lobe. In order to reduce steroids, persistent
cognitive deficits, and still raised antibody
titres, treatment with azathioprine was
initiated. With this therapy, the patient has
remained stable until now with slight
residual memory deficits but returned to
work recently. During therapy with levetir-
acetam, there is no evidence of seizures.
However, long-term follow-up is needed.
DISCUSSION
Here, we report a male patient with non-
paraneoplastic VGKC-ab and NMDAR-ab
associated limbic encephalitis. While the
mere occurrence of NMDAR-ab in male
patients is relatively rare and limited to a few
cases worldwide, to our knowledge this is
the first patient to harbour both VGKC-ab
and NMDAR-ab.
In patients with VGKC-ab associated LE,
clinical improvement is associated with titre
reduction. Since first testing for both anti-
bodies occurred 1 year after the onset of
symptoms and 6 months after the start of
steroid therapy, we cannot determine the
decline of the antibody titre after therapy.
However, both antibodies were still present at
this time and also detectable 6 months later.
While most patients with VGKC-ab-
associated limbic encephalitis present with
a subacute amnesic syndrome, seizures and
REM sleep behaviour disorder and do not
have an underlying malignancy,5 NMDAR-
ab-associated limbic encephalitis usually
affects young women with an ovarian tera-
toma.2 3 These patients usually present with
acute, severe psychiatric symptoms includ-
ing personality change, paranoia, anterograde
amnesia, agitation and/or catatonic stupor.
Autonomic symptoms and central hypo-
ventilation as well as seizures may also be
present in NMDAR-ab positive cases. Most
of these patients have lymphocytes in CSF,
while VGKC-ab-associated LE usually lacks
CSF changes.
The majority (85%) of previously
described patients suffering from NMDAR-
ab associated LE had prodromal flu-like
illness;3 however, our patient did not have
such symptoms, had a more insidious disease
progress and had no evidence for the pres-
ence of an underlying tumour. Clinical
presentation was more similar to VGKC-ab
associated LE than NMDAR-ab associated
LE. In our experience, none of the 60 control
patients were positive for antibodies to
NMDAR, and all patients with these anti-
bodies have an encephalitic illness (Irani and
Vincent unpublished results), so this test
seems to be specific.
This case emphasises the importance of
testing for antibodies in patients with sub-
acute onset of encephalopathy and suggests
that the clinical spectrum of NMDAR-ab
and VGKC-ab associated LE may turn out to
be broader than initially described. Since
both types of LE are associated with excel-
lent treatment responses, and since the ex-
tent of residual symptoms correlates with
time of treatment initiation, it is important
to recognise and treat autoimmune limbic
encephalitis early during disease course.
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